DrugBiological
Spartalizumab clinical trials
Also written PDR001.
Keep track of what changes. Save the spartalizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2017 (11)
| Year | Studies |
|---|---|
| 2015 | 3 |
| 2016 | 8 |
| 2017 | 11 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 10 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 34 · Other 13
Novartis Pharmaceuticals (34) · Asan Medical Center (2) · SOLTI Breast Cancer Research Group (1) · Columbia University (1) · Emory University (1) · Pancreatic Cancer Action Network (1) · Ruijin Hospital (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Trametinib (4) · Canakinumab (3) · Tislelizumab (2) · Decitabine (2) · Sabatolimab (2) · LCL161 (2) · Panobinostat (2) · CJM-112 (2)
Studies
Open first, then newest update. How each study uses spartalizumab is read from its arms, and is right about nine times in ten.
Testing it · 47
- Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's DiseaseRecruitingPhase 1Ruijin HospitalNCT07157345Written as PDR001
- Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT03891953Written as PDR001
- Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study TreatmentsActive, not recruitingPhase 1Novartis PharmaceuticalsNCT04058756Written as PDR001
- A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell CarcinomaCompletedEarly Phase 1Columbia UniversityNCT04028245Written as Spartalizumab
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedPhase 1Novartis PharmaceuticalsNCT04294160Written as Spartalizumab
- A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedPhase 1Novartis PharmaceuticalsNCT02936102Written as PDR001
- Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)TerminatedPhase 2Novartis PharmaceuticalsNCT04390763Written as Spartalizumab
- Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedPhase 1Novartis PharmaceuticalsNCT04000529Written as Spartalizumab
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedPhase 3Novartis PharmaceuticalsNCT02967692Written as Spartalizumab
- Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerCompletedPhase 1/2Emory UniversityNCT04191421Written as Spartalizumab
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedPhase 1Novartis PharmaceuticalsNCT03066648Written as PDR001
- KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid TumorsTerminatedEarly Phase 1Novartis PharmaceuticalsNCT04237649Written as PDR001
- A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) PatientsCompletedPhase 1Pancreatic Cancer Action NetworkNCT04581343Written as Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingPhase 2SOLTI Breast Cancer Research GroupNCT04802876Written as Spartalizumab
- Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT04310397Written as Spartalizumab
- A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedPhase 2Novartis PharmaceuticalsNCT03207867Written as PDR001
- Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedPhase 2Novartis PharmaceuticalsNCT04323436Written as Spartalizumab
- Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedPhase 1Novartis PharmaceuticalsNCT03301896Written as PDR001
- A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsTerminatedPhase 1/2Novartis PharmaceuticalsNCT02829723Written as PDR001
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedPhase 1/2Novartis PharmaceuticalsNCT02608268Written as PDR001
See all 47 studies that test spartalizumab →
Given in every arm · 12 — spartalizumab is usual care beside what is tested
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingPhase 2Novartis PharmaceuticalsNCT05201066Written as spartalizumab
- PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04544111Written as PDR001
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedPhase 1Novartis PharmaceuticalsNCT04895748Written as PDR001
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsCompletedPhase 1Novartis PharmaceuticalsNCT01351103Written as PDR001
- Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedPhase 1Dana-Farber Cancer InstituteNCT03294694Written as PDR001
- Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedPhase 1Novartis PharmaceuticalsNCT03742349Written as spartalizumab
- A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedPhase 1Novartis PharmaceuticalsNCT04261439Written as Spartalizumab
- FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB ExpressionCompletedPhase 1/2Novartis PharmaceuticalsNCT02325739Written as PDR001
- Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedPhase 2Novartis PharmaceuticalsNCT03484923Written as PDR001
- Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCCCompletedPhase 1/2Novartis PharmaceuticalsNCT02795429Written as Spartalizumab
- Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsTerminatedPhase 1Novartis PharmaceuticalsNCT02607813Written as PDR001
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsTerminatedPhase 1Novartis PharmaceuticalsNCT03064854Written as PDR001
Codes
What other systems call spartalizumab · ClinicalTrials.gg INT001467
- MeSH (NLM) C000711728spartalizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QOG25L6Z8ZSPARTALIZUMABConfirmed FDA, NLM
- NCI Thesaurus C121625SpartalizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711728 | spartalizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QOG25L6Z8Z | SPARTALIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C121625 | Spartalizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.